SecBot SecBot
PRESS-RELEASE ·Filed May 28, 2026

INKT

MiNK Therapeutics
NEUTRAL
Impact 4/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Traders should view this as an expected clinical execution update with no material stock-moving data. The next meaningful catalyst is the preliminary data readout in 2H 2026. Until then, there is no new fundamental information to alter the risk/reward profile.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+60
Entry
$12.20
T+0 close · May 28, 2026 · via day close
Latest settled
0.00%
T+60 · $12.20
Vs SPY
−1.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 28 $12.20entry
  2. T+1 · 6mo ago 0.00%α −0.24% · $12.20
  3. T+5 · 6mo ago +4.59%α +4.64% · $12.76
  4. T+20 · 5mo ago −4.59%α −1.45% · $11.64
  5. T+60 · 3mo ago 0.00%α −1.74% · $12.20
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics announced first patient dosing in a randomized Phase 2 trial (C-1300-02) evaluating agenT-797 for severe acute lung injury/ARDS. This is a clinical milestone with no revenue or earnings data, and preliminary efficacy readout is not expected until 2H 2026, making the near-term stock impact limited.

Key Facts

  • First patient dosed in randomized Phase 2 trial (C-1300-02) for agenT-797 in severe acute lung injury/ARDS patients
  • Trial compares agenT-797 + standard of care vs placebo + standard of care; primary endpoints include survival, ventilator-free days, and ICU recovery
  • Dosing occurred at First Lviv Territorial Medical Union in Ukraine, with U.S. site expansion underway
  • Preliminary data expected in second half of 2026, no near-term catalyst
  • agenT-797 is an off-the-shelf allogeneic iNKT cell therapy, delivered without patient-specific manufacturing or HLA matching
  • No financial figures, guidance, or material agreements disclosed in the press release

Financial Impact

No revenue, earnings, or financial guidance disclosed, pre-revenue clinical-stage company with $51M market cap

Risk Factors

  • Phase 2 trial may fail to meet endpoints, potentially wiping out clinical value of agenT-797 in this indication
  • Enrollment in Ukraine faces geopolitical and operational risks
  • Pre-revenue company with limited cash runway, future financing risk exists

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3302945

Track record

21 reports on INKT

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Viewing Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (10h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 28, 2026